ISTA Pharmaceuticals

From Wikipedia, the free encyclopedia
ISTA Pharmaceuticals, Inc.
Company typeSubsidiary
IndustryPharmaceuticals
Founded1992
HeadquartersIrvine, California
Key people
Vicente Anido Jr., Ph.D.
(President, Chief Executive Officer)
Glenn E. Davis
(Vice President, Chief Compliance Officer)
Marvin J. Garrett
(Vice President, Regulatory Affairs, Quality & Compliance)
Kathleen McGinley
(Vice President, Human Resources & Corporate Services)
ProductsBromday, Bepreve, Xibrom, Istalol, Vitrase
Websitewww.istavision.com

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012.[2] Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million.[3] In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[4]

Products[edit]

  • Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[5]
  • Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[6]
  • Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
  • Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[7]
  • Vitrase (hyaluronidase injection) Ovine, 200 USP units/mL for use as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[8]

Litigation[edit]

On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[9]

References[edit]

  1. ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved October 28, 2009.
  2. ^ Lattman, Peter (26 March 2012). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved January 29, 2019.
  3. ^ Lattman, Peter (2012-03-26). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved 2019-10-21.
  4. ^ Scott, Mark (4 September 2012). "Valeant Sticks to Torrid Pace of Deal-Making". DealBook. Retrieved January 29, 2019.
  5. ^ "BROMDAY™ | Products". Archived from the original on 2011-07-13. Retrieved March 21, 2011.
  6. ^ "Relief from Allergic Conjunctivitis - BEPREVE : Bausch + Lomb". www.Bausch.com. Retrieved January 29, 2019.
  7. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  8. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  9. ^ "ISTA Pharmaceuticals Inc. Pleads Guilty to Federal Felony Charges; Will Pay $33.5 Million to Resolve Criminal Liability and False Claims Act Allegations". www.Justice.gov. May 24, 2013. Retrieved January 29, 2019.

External links[edit]